[APASL2011]Anemia in Patients with Chronic Hepatitis C during Anti-viral Therapy ——Interview with Prof.Mitchell L. ShiffmanProf. Shiffman: The major cause of anemia in patients with hepatitis C receiving treatment is twofold: number one is a hemolytic process， meaning red blood cells burst from ribavirin; and number two is bone marrow suppression from taking interferon preventing the bone marrow from robustly responding to the anemia generated by the ribavirin. So it is a two-drug， two-mechanism cause.阅读数：1113详细阅读>>
[APASL2011]Present and Future Prospects for Drug Therapy of Hepatic——Encephalopathy-Interview with Dr Praveen SharmaDr Sharma: Currently we are using either non-absorbable disaccharides such as lactitol or lactulose as well as antibiotics which are poorly absorbed from the gut. The main purpose of these agents is to reduce ammonia levels because it is ammonia which is the main precursor for the pathogenesis of HE. However although many people are using these non-absorbable disaccharides the evidence to support their use is not there:阅读数：1217详细阅读>>
